Neumora Therapeutics (NMRA)
Develops precision medicines for brain diseases using neuroscience and data science.
Something off on this page? Send us feedback.
Develops clinical-stage precision-medicine programs for neuropsychiatric and neurodegenerative brain diseases. Its approach combines translational, clinical, and computational tools with neuroscience drug development.
Builds clinical-stage programs for neuropsychiatric and neurodegenerative brain diseases using translational, clinical, and computational tools. Its portfolio draws on internal research, acquired private companies, and Amgen license agreements.
Founded in 2019 and launched publicly as Neumora in 2021, it combines data science and neuroscience to generate precision-medicine insights. Its development model depends on clinical-trial outcomes; the company discontinued navacaprant after the KOASTAL program did not meet primary or key secondary endpoints.
In 2020, it assembled portions of its initial research and drug-candidate base through acquisitions. Listed on Nasdaq since 2023, it has its principal executive office in Watertown, Massachusetts.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 13, 2026 | RBC Capital | Reiterate | Outperform | $7 | $5 | |
| Jun 18, 2026 | Mizuho Securities | Target | $6 | $4 | ||
| Feb 17, 2026 | William Blair | Upgrade | Market Perform | Outperform | ||
| Jan 12, 2026 | Leerink Partners | Target | $8 | |||
| Jan 5, 2026 | Mizuho Securities | Target | $20 | $6 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $116.8M · Total debt $340.0K · Total assets $125.2M · Shareholders' equity $44.5M
- Revenue
- $0
- Operating income
- −$42.2M
- Net income
- −$43.1M
No dividends on record.
| Institutions121 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 37.43% | 70.33M shares | |
| Insiders7 holders · as of Aug 21, 2026 | 4.71% | 8.86M shares | |
| Strategic holders1 holder · as of Sep 27, 2023 | 18.82% | 35.37M shares | |
| Otherremainder | ≈ 39.04% | 73.34M shares |
187.90M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Amgen IncStrategic10 percent owner | 18.82% | 35.37M | 13Dfiled Sep 27, 2023 ↗ |
Siren, L.L.C.Institution | 4.52% | 8.50M | 13Fas of Mar 31, 2026 |
Paul L. Berns1Insiderdirector, officer: See Remarks | 4.37% | 8.23M | 13Gfiled Feb 19, 2026 ↗ |
SoftBank Group Corp.Institution | 3.24% | 6.09M | 13Fas of Mar 31, 2026 |
Perceptive Advisors LLCInstitution | 2.72% | 5.10M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Paul L. Berns's transaction reports restate only vehicles that traded; the 2025 ownership statement (8.23M) less the 23.7K net shares sold since is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Daljit Singh Aurora | officer: See Remarks | −41,608 | $1.60 |
| Aug 20, 2026 | Daljit Singh Aurora | officer: See Remarks | −134,452 | $1.51 |
| Aug 19, 2026 | Daljit Singh Aurora | officer: See Remarks | −61,918 | $1.65 |
| Aug 18, 2026 | Daljit Singh Aurora | officer: See Remarks | −69,149 | $1.59 |
| Aug 17, 2026 | Daljit Singh Aurora | officer: See Remarks | −146,706 | $1.50 |
- Bristol-Myers Squibb
An approved muscarinic option for adult schizophrenia
- Eli Lilly
Marketed and investigational obesity therapies
- BioXcel Therapeutics
An investigational acute option for Alzheimer's agitation
- AbbVie
M4 PAM programs for schizophrenia and psychosis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Neumora Therapeutics | $1.38 | +3.38% | $255.7M | — | — | — | — |
| Bristol-Myers Squibb | $67.88 | +0.34% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Eli Lilly | $1,160.08 | +0.06% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| BioXcel Therapeutics | $0.1189 | +8.98% | $3.3M | — | — | 4.5 | +51.7% |
| AbbVie | $261.54 | −0.06% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Median | 38.9 | 17.2 | 5.8 | +28.9% |